GlassScriptPhysician profile
Kameron B Price
NPI 1982368262
$2,107.37
in general payments reported to CMS, 2019-2025
23 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $325 · 2023: $807 · 2024: $516 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,782.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $332.98 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $255.61 | 2022-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223.34 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $154.42 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $148.56 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $132.82 | 2022-2025 | Trintellix |
| Axsome Therapeutics, INC. | $116.03 | 2023-2025 | Auvelity |
| Alkermes, INC. | $112.79 | 2022-2025 | Lybalvi, Aristada |
| Tris Pharma INC | $108.73 | 2022-2024 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $98.64 | 2022-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $83.67 | 2022-2023 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $66.86 | 2022-2023 | Austedo |
| Idorsia Pharmaceuticals US INC | $40.57 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $39.94 | 2024 | Xelstrym, Secuado |
| Bausch Health US, LLC | $35.19 | 2023-2025 | Aplenzin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $31.51 | 2022 | |
| Lundbeck LLC | $24.10 | 2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $20.61 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $18.95 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $18.55 | 2023 | Jornay Pm |
| Neos Therapeutics, LP | $16.72 | 2023 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $13.93 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.85 | 2023 | Invega Sustenna, Invega Trinza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kameron Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.